Wormont-FX Tablet is a combination pharmaceutical formulation containing Montelukast 10 mg and Fexofenadine 120 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, functions by selectively blocking leukotriene D4 receptors in the respiratory tract, thereby reducing bronchoconstriction, inflammation, and mucus production. Fexofenadine, a second-generation antihistamine, competitively inhibits peripheral H1 receptors, alleviating symptoms like sneezing, nasal congestion, and pruritus without causing significant sedation. The synergistic action of these two agents provides comprehensive relief from allergic manifestations by targeting multiple pathways involved in the allergic response. Wormont-FX is typically administered orally once daily, with or without food, as prescribed by a healthcare professional. It is well-tolerated, though patients should be monitored for potential adverse effects such as headache, gastrointestinal discomfort, or hypersensitivity reactions. Caution is advised in patients with hepatic or renal impairment, and drug interactions should be considered, particularly with erythromycin, ketoconazole, or other CYP450 modulators. Wormont-FX Tablet offers an effective therapeutic option for patients requiring dual-action treatment for persistent allergic symptoms, improving quality of life through targeted pharmacological intervention.